SEC Form 4 · accession 0001192482-19-000048
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James E Fickenscher
Officer — Chief Financial Officer
Period of report
Jan 24, 2019
Accepted (ET)
Jan 28, 2019 · 4:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.65 | Jan 24, 2019 | A | 88,099 | A | — | Jan 24, 2029 | Common Stock | 88,099 | 88,099 | D |
Explanation of responses
- F1The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company.